Asia
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
WuXi Biologics was amongst those on the list, with the U.S. stating that it was unable to verify the legitimacy and reliability of the company in its use of U.S. exports.
Pfizer has filed a lawsuit against execs at Regor Therapeutics after an investigation pointing company trade secrets were used to develop therapeutics at the center of Regor’s partnership with Eli Lilly.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.
According to a statement from China’s NHSA, AstraZeneca staff members are suspected of tampering with the genetic testing results of cancer patients in order to defraud medical insurance funds.
Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Although most of the news about the effectiveness and endurance of COVID-19 vaccines has focused on antibody titers, not as much has been reported on their effect on other parts of the immune system that offer longer-term protection, such as T cells. For that and more, continue reading.
PRESS RELEASES